Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + Platinum-Gemcitabine in First-Line Recurrent/Metastatic NPC
NCT04458909Phase 3Terminated
- Sponsor
- National Cancer Institute
- Start
- Dec 2020
- Primary completion
- Aug 2023
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 3 trial of nivolumab in nasopharyngeal carcinoma (NPC), sponsored by National Cancer Institute. Started Dec 2020; status: terminated.
02
Drugs
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT04458909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04458909.